Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 2 靖宫颗粒与安慰剂平行对照治疗气滞血瘀证型子宫肌瘤的随机、双盲、多中心Ⅱb期临床试验
[Translation] A randomized, double-blind, multicenter phase Ⅱb clinical trial of Jinggong granules versus placebo in the treatment of uterine fibroids of Qi stagnation and blood stasis syndrome
通过多中心、随机、双盲、安慰剂平行对照研究,评价靖宫颗粒治疗气滞血瘀证型子宫肌瘤患者的有效性和安全性。
[Translation] A multicenter, randomized, double-blind, placebo-controlled parallel study was conducted to evaluate the efficacy and safety of Jinggong Granule in the treatment of patients with uterine fibroids of Qi stagnation and blood stasis syndrome.
100 Clinical Results associated with Fuzhou Changfuxing New Drug Development Co., Ltd.
0 Patents (Medical) associated with Fuzhou Changfuxing New Drug Development Co., Ltd.
100 Deals associated with Fuzhou Changfuxing New Drug Development Co., Ltd.
100 Translational Medicine associated with Fuzhou Changfuxing New Drug Development Co., Ltd.